Ratings by H.C. Wainwright (Boobalan Pachaiyappan)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/26/2026 | Cingulate | CING | Maintain | Buy (Buy) |
|
Details | ||
| 5/8/2026 | Entrada Therapeutics | TRDA | Downgrade | Neutral (Buy) |
6.85 (7.59) |
10.8% | Details | |
| 6/2/2025 | Entrada Therapeutics | TRDA | Maintain | Buy (Buy) |
|
Details | ||
| 4/14/2025 | PolyPid Ltd. | PYPD | Maintain | Buy (Buy) |
|
Details | ||
| 3/31/2025 | Entrada Therapeutics | TRDA | Maintain | Buy (Buy) |
|
Details | ||
| 2/25/2025 | Entrada Therapeutics | TRDA | Maintain | Buy (Buy) |
|
Details | ||
| 2/4/2025 | Entrada Therapeutics | TRDA | Maintain | Buy (Buy) |
|
Details | ||
| 1/30/2025 | Cingulate | CING | Maintain | Buy (N/A) |
|
Details | ||
| 12/26/2024 | PolyPid Ltd. | PYPD | Maintain | Buy (N/A) |
|
Details | ||
| 11/6/2024 | Entrada Therapeutics | TRDA | Maintain | Buy (N/A) |
|
Details | ||
| 11/4/2024 | Hoth Therapeutics | HOTH | Maintain | Buy (Buy) |
|
Details | ||
| 10/16/2024 | Hoth Therapeutics | HOTH | Maintain | Buy (Buy) |
|
Details | ||
| 10/2/2024 | PolyPid Ltd. | PYPD | Maintain | Buy (Buy) |
|
Details | ||
| 6/25/2024 | Entrada Therapeutics | TRDA | Maintain | Buy (N/A) |
|
Details | ||
| 2/15/2024 | PolyPid Ltd. | PYPD | Maintain | Buy (N/A) |
|
Details | ||
| 2/5/2024 | Hoth Therapeutics | HOTH | New Coverage | Buy (N/A) |
1.29 (1.36) |
5.43% | Details | |
| 1/8/2024 | Cingulate | CING | Maintain | Buy (N/A) |
|
Details | ||
| 11/27/2023 | Entrada Therapeutics | TRDA | Maintain | Buy (N/A) |
|
Details | ||
| 10/12/2023 | PolyPid Ltd. | PYPD | New Coverage | Buy (N/A) |
4.00 (5.05) |
26.25% | Details | |
| 9/28/2023 | Galecto | GLTO | Downgrade | Neutral (Buy) |
0.70 (28.69) |
3998.57% | Details | |
| 9/26/2023 | Cingulate | CING | Maintain | Buy (N/A) |
|
Details | ||
| 9/25/2023 | Ensysce Biosciences Inc. | ENSC | Maintain | Buy (N/A) |
|
Details | ||
| 9/18/2023 | Anebulo Pharmaceuticals | ANEB | New Coverage | Buy (N/A) |
3.20 (0.36) |
-88.75% | Details | |
| 7/3/2023 | Ensysce Biosciences Inc. | ENSC | New Coverage | Buy (N/A) |
1.80 (0.30) |
-83.33% | Details | |
| 4/3/2023 | Entrada Therapeutics | TRDA | New Coverage | Buy (N/A) |
14.50 (6.85) |
-52.76% | Details |
